Latest Share Chat

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Buy GSK Shares
Add GSK to Watchlist
Add GSK to Alert

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 1,780.50

Bid: 1,773.00

Ask: 1,790.00

Change: 0.00 (0.00%)

Spread: 17.00 (0.959%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 1,780.50

Last checked at -

2 Apr 2014 11:48

London midday: Markets edge higher but gains limited

- Stocks extend three-week high - ECB, US data ahead - Antofagasta unharmed by Chile quake - Sports Direct extends gains on expansion potential techMARK 2,795.73 +0.42% FTSE 100 6,666.62 +0.21% FTSE 250 16,470.77 +0.39% The FTSE 100 had pushed into positive territory by Wednesday lunchtime, but ga

2 Apr 2014 11:30

DIRECTOR DEALINGS: Glaxo Non-Executives Awarded Shares, ADSs

LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said a group of non-executives was awarded shares and American Depositary Shares at GBP16.08 per share and USD53.75 each respectively Monday.

Details are as follows.

2 Apr 2014 10:47

UK WINNERS & LOSERS: Marks & Spencer Rises On Expansion Plans

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.

-------

FTSE 100 - WINNERS

Marks and Spencer Group, up 2.4%. The retailer has announced that it is planning to ope

2 Apr 2014 10:27

TOP NEWS: BP To Shutter Oil Refinery In Brisbane, Australia

LONDON (Alliance News) - The following is a summary of top news stories Wednesday.
----------
COMPANIES
---------- BP PLC announced it intends to halt refinery operations at its major Bulwer Island refinery in Brisbane, Australia by mid-20

2 Apr 2014 10:03

Glaxo clinical trial disappointment in the price, says Panmure

Panmure Gordon has said that the disappointing outcome of GlaxoSmithKline's (GSK) clinical trial for its therapeutic cancer vaccine MAGE-A3 is already priced into the stock. The broker kept its 'hold' recommendation and 1,750p target price. The MAGRIT trial, a phase three trial of its MAGE-A3 anti

2 Apr 2014 08:59

London open: Markets hold at three-week high

- Markets flat ahead of ECB, US data - Antofagasta operations unaffected by Chile quake - Domino's, ASOS impress with results techMARK 2,788.47 +0.16% FTSE 100 6,650.51 -0.03% FTSE 250 16,413.15 +0.03% UK stocks were flat at a three-week high on Wednesday morning as investors paused for breath ahe

2 Apr 2014 08:48

Wednesday broker round-up UPDATE

Aberdeen Asset Management: Canaccord Genuity reduces target price from 540p to 460p, while its buy recommendation is kept. Anglo American: JP Morgan ups target price from 1260p to 1300p, while leaving its underweight rating unchanged. Aviva: JP Morgan raises target price from 528p to 570p maintain

2 Apr 2014 08:02

UPDATE 1-GlaxoSmithKline throws in towel on lung cancer vaccine trial

* Lung cancer trial with MAGE-A3 therapeutic vaccine stopped * Not possible to find patient sub-group that might benefit * Research into vaccine's use in melanoma continues * GSK shares down 0.7 percent (Adds analyst reaction, latest share price) By Ben Hirschler L

2 Apr 2014 07:40

Glaxo 'disappointed' after stopping lung cancer trial

GlaxoSmithKline (GSK) said it was 'disappointed' after having to call an end to its clinical trial for its treatment for non-small cell lung cancer (NSCLC). The MAGRIT trial, a phase three trial of its MAGE-A3 antigen-specific cancer immunotherapeutic in NSCLC patients, has been ended as GSK couldn

2 Apr 2014 07:38

UK MORNING BRIEFING: FirstGroup In Line; Go-Ahead Tipped By Goldman

LONDON (Alliance News) - Shares have opened flat to slightly down Wednesday, despite a record close in the US and strong UK house price data.

Goldman Sachs has added Go-Ahead Group to its Conviction Buy List with a price target of 2,310 pence. The bus and train comp

2 Apr 2014 07:04

Glaxo Stops MAGE-A3 Cancer Treatment Phase III Trial

LONDON (Alliance News) - GlaxoSmithKline PLC Wednesday said it had chosen to stop the Phase III trial of its MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer patients, as it said it would not be possible to identify a sub-population of MAGE-A3 positive patients with a specific gene

2 Apr 2014 06:37

GSK throws in towel on lung cancer vaccine trial

LONDON, April 2 (Reuters) - GlaxoSmithKline has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit. The decision comes less than two weeks after the British drugmaker said

1 Apr 2014 23:10

GSK's ViiV unit adds new HIV drug to AIDS patent pool

LONDON, April 1(Reuters) - GlaxoSmithKline's AIDS drugs business is to add one of its latest HIV medicines to a patent pool - cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the British drugmaker, said t

1 Apr 2014 23:09

GSK's ViiV unit adds new HIV drug to AIDS patent pool

1 Apr 2014 22:58

FDA defends generic drug label proposal at U.S. House hearing

April 1 (Reuters) - The U.S. Food and Drug Administration on Tuesday defended its proposal to require generic drugmakers to update the prescribing information on their products if they become aware of new safety information, a move the industry says will open them to product liability lawsuits an

Latest Share Chat

Glaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Login to your account

Quickpicks are a member only feature

Login to your account